Apellis Pharmaceuticals Inc (APLS)

Currency in USD
41.03
-0.03(-0.07%)
Closed·
Showing Apellis Pharma historical data. For real-time data please try another search
Fair Value
Day's Range
41.0341.07
52 wk Range
16.6141.14
Key Statistics
Prev. Close
41.03
Open
41.05
Day's Range
41.03-41.07
52 wk Range
16.61-41.14
Volume
68.61M
Average Volume (3m)
6.42M
1-Year Change
135.1289%
Book Value / Share
3.25
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
APLS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
40.93
Downside
-0.25%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

1 Buy
18 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 40.93
(-0.25% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Apellis Pharmaceuticals Inc Earnings Call Summary for Q4/2025

  • Q4 2025 revenue reached $200M, exceeding forecast of $198.82M; full-year revenue hit $1B including $275M one-time payment.
  • Syfovre generated $155M and Empaveli $35M in Q4; strong product demand continues despite 6.36% pre-market stock decline to $21.04.
  • Operating expenses rose to $251M from $239M year-over-year, driven by new pivotal trials and milestone payments.
  • 2026 guidance projects modestly higher expenses; planned Syfovre prefilled syringe launch and AI-enabled OCT technology development underway.
  • Company managing $94M convertible debt maturing September 2026; maintains strong liquidity with 3.54 current ratio.
Last Updated: 2026-02-24, 09:48 a/m
Read Full Transcript

Earnings

Latest Release
May 07, 2026
EPS / Forecast
0.15 / -0.34
Revenue / Forecast
268.3M / 203.58M
EPS Revisions
Last 90 days

APLS Income Statement

Compare APLS to Peers and Sector

Metrics to compare
APLS
Peers
Sector
Relationship
P/E Ratio
39.4x5.3x−0.4x
PEG Ratio
2.120.030.00
Price/Book
12.7x3.5x2.6x
Price / LTM Sales
4.8x6.2x3.0x
Upside (Analyst Target)
−0.3%157.9%58.4%
Fair Value Upside
Unlock13.9%8.6%Unlock

People Also Watch

37.77
PACS
+3.22%
20.66
RELY
-2.09%
208.98
GTLS
+0.48%
140.73
ICLR
-3.61%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.